From molecular biomarkers to clinical outcomes after microneedling: a patented multi-target bioactive complex promoting skin longevity (ESDR 2026) - Oct 5, 2026 - Abstract #314; "1-LGVTY, a patented complex of baicalin, chlorogenic acid, sodium carboxymethyl beta-glucan and oligosaccharides, was assessed for translation of its molecular anti-aging activity through ex-vivo experimental model into clinical benefit when delivered as a 7.5% serum in post-procedure care associated with collagen precursor peptides...Tolerance was excellent. This bench-to-bedside translation shows that a multi-target bioactive complex modulating key hallmarks of skin aging like chronic inflammation delivers clinical benefit, supporting adjunctive use after aesthetic procedures."
Biomarker • Clinical • Clinical data • Aesthetic Medicine • Inflammation • IL6 • Tyrosinase
|
|
Julien Demaude 1; Maïwenn Campeaux 1; Andrea Cavagnino 2; Martin Baraibar 2; Mike Amzallag 3; Joel Aknin 4; Sylvie Boisnic 5; Stephane Wilmet 1; Raphael Aknin 1
|